Lund University Hospital

sus.se

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

65

Active

14

Phase 3

10

Total enrollment

12,193

Pipeline matrix

Showing 9 of 9 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
177Lu-DOTATOC1
Capecitabine1
epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab1
epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab1
Fluorouracil1
Oxaliplatin1
Irinotecan1
Pemigatinib1
Retifanlimab1

Next readouts

  • 2026-10-01
  • 2026-11-30
  • 2027-12-31
  • 2035-09

Top conditions

  • Colorectal Cancer3
  • Breast Cancer3
  • Neuroendocrine Tumors2
  • Opioid Use2
  • Lung Transplant Failure2
  • Lung Transplant; Complications2
  • Cardiovascular Diseases2
  • Metastatic Breast Cancer2

Frequently asked questions about Lund University Hospital

How many clinical trials does Lund University Hospital have on ClinicalTrials.gov?
Lund University Hospital is listed as the lead sponsor on 65 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
How many of Lund University Hospital's trials are in Phase 3?
10 of Lund University Hospital's trials are in Phase 3, spread across 9 active drug programs.
What therapeutic areas does Lund University Hospital focus on?
Lund University Hospital's most-studied conditions on ClinicalTrials.gov are Colorectal Cancer, Breast Cancer, Neuroendocrine Tumors, Opioid Use, Lung Transplant Failure.
When are Lund University Hospital's next clinical trial readouts?
Lund University Hospital has 4 upcoming primary-completion readouts tracked here; the soonest is “Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.”, expected around 2026-10-01.